Liarozole - A novel treatment approach for advanced prostate cancer: Results of a large randomized trial versus cyproterone acetate

Urology

Volumn 52, Issue 1, 1998, Pages 72-81

  Debruyne, Frans J M ^a   Murray, Robin ^b   Fradet, Yves ^b   Johansson, Jan E ^b   Tyrrell, Chris ^b   Boccardo, Francesco ^b   Denis, Louis ^b   Marberger, J Michael ^b   Brune, Daniel ^b   Rassweiler, Jens ^b   Vangeneugden, Tony ^b   Bruynseels, Jan ^b   Janssens, Monique ^b   De Porre, Peter ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN; LIAROZOLE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRY SKIN; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; VOMITING;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CYPROTERONE ACETATE; DISEASE PROGRESSION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0032126721     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00129-0     Document Type: Article

References (28)

1. 1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
2. 2. Badalament RA, and Drago JR: Prostate cancer, in Bone RC (Ed): Disease-a-Month. St Louis, Mosby-Year Book, Littleton, 1991.
3. 3. Pavone-Macaluso M, de Voogt HJ, Viggiano G, et al: Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European organisation for research on treatment of cancer urological group. J Urol 136: 624-631, 1986.
4. 4. Prostate Cancer Trialists Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346: 265-269, 1995.
5. 5. Smith RB, Walsh PC, and Goodwin W: Cyproterone acetate in the treatment of advanced carcinoma of the prostate. J Urol 110: 106-108, 1973.
6. 6. Product Monograph, Androcur 50 mg. Schering AG, Berlin, April 26, 1985.
7. 7. Goldenberg SL, and Bruchovsky N: Use of cyproterone acetate in prostate cancer. Urol Clin North Am 18: 111-122, 1991.
8. 8. Vogelzang NJ: Editorial: one hundred thirteen men with hormone-refractory prostate cancer died today. J Clin Oncol 14: 1753-1755, 1996.
9. 9. Favennec L, and Cals M-J: The biological effects of retinoids on cell differentiation and proliferation. J Clin Chem Clin Biochem 26: 479-489, 1988.
10. 10. Lotan R: Mechanisms of action of retinoids. Cancer Bull 38: 113-116, 1986.
11. 11. Trump D, Smith D, Stiff D, et al: All-trans retinoic acid (ATRA) in hormone refractory prostate cancer: ineffectiveness due to failure of drug delivery? Proc Am Soc Clin Oncol 13: 241, 1994.
12. 12. David M, Hodak E, and Lowe NT: Adverse effects of retinoids. Med Tox Adverse Exp 3: 273-288, 1988.
13. 13. Dimery IW, Hong WK, Lu JJ, et al: Phase I trial of α-tocophenol effects on 13-cis-retinoic acid toxicity. Ann Oncol 8: 85-89, 1997.
14. 14. Van Ginckel R, De Coster R, Wouters W, et al: Antitumoral effects of R075251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats. Prostate 16: 313-323, 1990.
15. 15. Denis L: Liarozole-fumarate (LIA), a novel antitumoral drug: clinical update. Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer, Quebec City, Canada, September 21-23, 1995, p 45.
16. 16. Newling D: Criteria of response to treatment in advanced prostatic cancer. Baillieres Clin Oncol 2: 505-519, 1988.
17. 17. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34: 187-220, 1972.
18. 18. Collett D: Modelling Survival Data in Medical Research. London, Chapman and Hall, 1994.
19. 19. Anderson JR, Cain KC, and Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1(11): 710-719, 1983.
20. 20. Buyse M, and Piedbois P: On the relationship between response to treatment and survival time. Stat Med 15: 2797-2812, 1996.
21. 21. de Voogt HJ, Suciu S, Sylvester R, et al: Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. J Urol 141: 883-888, 1989.
22. 22. Fosså SD, Paus E, Lindegaard M, et al: Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. Br J Urol 69: 175-179, 1992.
23. 23. Soloway MS: The importance of prognostic factors in advanced prostate cancer. Cancer 66(suppl): 1017-1021, 1990.
24. 24. Akazawa K, Nakamura T, and Palesch Y: Power of logrank test and Cox regression model in clinical trials with heterogenous samples. Stat Med 16: 583-597, 1997.
25. 25. Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607-615, 1993.
26. 26. Siddall JK, Hetherington JW, Cooper EH, et al: Biochemical monitoring of carcinoma of the prostate treated with an LHRH analogue (Zoladex). J Urol 58: 676-682, 1986.
27. 27. Eisenberger MA, Simon RS, O'Swyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3: 827-841, 1985.
28. 28. Denis L, Debruyne FMJ, et al: Early clinical experience with liarozole in patients with progressive prostate cancer. Eur J Cancer 34: 469-475, 1998.